Cold atmospheric plasma for selectively ablating metastatic breast cancer cells.
Traditional breast cancer treatments such as surgery and radiotherapy contain many inherent limitations with regards to incomplete and nonselective tumor ablation. Cold atmospheric plasma (CAP) is an ionized gas where the ion temperature is close to room temperature. It contains electrons, charged p...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3770688?pdf=render |
id |
doaj-800df950b390450d8e804059ab3d3420 |
---|---|
record_format |
Article |
spelling |
doaj-800df950b390450d8e804059ab3d34202020-11-25T02:16:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0189e7374110.1371/journal.pone.0073741Cold atmospheric plasma for selectively ablating metastatic breast cancer cells.Mian WangBenjamin HolmesXiaoqian ChengWei ZhuMichael KeidarLijie Grace ZhangTraditional breast cancer treatments such as surgery and radiotherapy contain many inherent limitations with regards to incomplete and nonselective tumor ablation. Cold atmospheric plasma (CAP) is an ionized gas where the ion temperature is close to room temperature. It contains electrons, charged particles, radicals, various excited molecules, UV photons and transient electric fields. These various compositional elements have the potential to either enhance and promote cellular activity, or disrupt and destroy them. In particular, based on this unique composition, CAP could offer a minimally-invasive surgical approach allowing for specific cancer cell or tumor tissue removal without influencing healthy cells. Thus, the objective of this research is to investigate a novel CAP-based therapy for selectively bone metastatic breast cancer treatment. For this purpose, human metastatic breast cancer (BrCa) cells and bone marrow derived human mesenchymal stem cells (MSCs) were separately treated with CAP, and behavioral changes were evaluated after 1, 3, and 5 days of culture. With different treatment times, different BrCa and MSC cell responses were observed. Our results showed that BrCa cells were more sensitive to these CAP treatments than MSCs under plasma dose conditions tested. It demonstrated that CAP can selectively ablate metastatic BrCa cells in vitro without damaging healthy MSCs at the metastatic bone site. In addition, our study showed that CAP treatment can significantly inhibit the migration and invasion of BrCa cells. The results suggest the great potential of CAP for breast cancer therapy.http://europepmc.org/articles/PMC3770688?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mian Wang Benjamin Holmes Xiaoqian Cheng Wei Zhu Michael Keidar Lijie Grace Zhang |
spellingShingle |
Mian Wang Benjamin Holmes Xiaoqian Cheng Wei Zhu Michael Keidar Lijie Grace Zhang Cold atmospheric plasma for selectively ablating metastatic breast cancer cells. PLoS ONE |
author_facet |
Mian Wang Benjamin Holmes Xiaoqian Cheng Wei Zhu Michael Keidar Lijie Grace Zhang |
author_sort |
Mian Wang |
title |
Cold atmospheric plasma for selectively ablating metastatic breast cancer cells. |
title_short |
Cold atmospheric plasma for selectively ablating metastatic breast cancer cells. |
title_full |
Cold atmospheric plasma for selectively ablating metastatic breast cancer cells. |
title_fullStr |
Cold atmospheric plasma for selectively ablating metastatic breast cancer cells. |
title_full_unstemmed |
Cold atmospheric plasma for selectively ablating metastatic breast cancer cells. |
title_sort |
cold atmospheric plasma for selectively ablating metastatic breast cancer cells. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Traditional breast cancer treatments such as surgery and radiotherapy contain many inherent limitations with regards to incomplete and nonselective tumor ablation. Cold atmospheric plasma (CAP) is an ionized gas where the ion temperature is close to room temperature. It contains electrons, charged particles, radicals, various excited molecules, UV photons and transient electric fields. These various compositional elements have the potential to either enhance and promote cellular activity, or disrupt and destroy them. In particular, based on this unique composition, CAP could offer a minimally-invasive surgical approach allowing for specific cancer cell or tumor tissue removal without influencing healthy cells. Thus, the objective of this research is to investigate a novel CAP-based therapy for selectively bone metastatic breast cancer treatment. For this purpose, human metastatic breast cancer (BrCa) cells and bone marrow derived human mesenchymal stem cells (MSCs) were separately treated with CAP, and behavioral changes were evaluated after 1, 3, and 5 days of culture. With different treatment times, different BrCa and MSC cell responses were observed. Our results showed that BrCa cells were more sensitive to these CAP treatments than MSCs under plasma dose conditions tested. It demonstrated that CAP can selectively ablate metastatic BrCa cells in vitro without damaging healthy MSCs at the metastatic bone site. In addition, our study showed that CAP treatment can significantly inhibit the migration and invasion of BrCa cells. The results suggest the great potential of CAP for breast cancer therapy. |
url |
http://europepmc.org/articles/PMC3770688?pdf=render |
work_keys_str_mv |
AT mianwang coldatmosphericplasmaforselectivelyablatingmetastaticbreastcancercells AT benjaminholmes coldatmosphericplasmaforselectivelyablatingmetastaticbreastcancercells AT xiaoqiancheng coldatmosphericplasmaforselectivelyablatingmetastaticbreastcancercells AT weizhu coldatmosphericplasmaforselectivelyablatingmetastaticbreastcancercells AT michaelkeidar coldatmosphericplasmaforselectivelyablatingmetastaticbreastcancercells AT lijiegracezhang coldatmosphericplasmaforselectivelyablatingmetastaticbreastcancercells |
_version_ |
1724889771516362752 |